Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Comparative Study on the Efficacy of the Combination of Micropulse Laser With or Without Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinal Disease

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06468540

Enrollment

Registered

2024-06-21

Start date

2024-06-15

Completion date

2025-12-15

Last updated

2024-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy, Micropulse Laser, Photodynamic Therapy

Brief summary

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Age \>18 years old. * The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula. * Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment. * Patients had follow-up data before and after treatment for 1 month and at least 6 months.

Exclusion criteria

* Patients with other fundus diseases or refractive interstitial opacity. * During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received. * Various reasons led to incomplete patient data.

Design outcomes

Primary

Measure	Time frame	Description
BCVA	1 month and 6 months	Best-corrected visual acuity using logMAR
CRT	1 month and 6 months	Central retinal thickness on OCT

Secondary

Measure	Time frame	Description
SFCT	1 month and 6 months	subfoveal choroidal thickness on OCTA

Outcome results